Medications in dermatology are safer and more efficient than they used to be

Britney N. WilsonCenter for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Esther A. BaloghCenter for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Steven R. FeldmanCenter for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA;Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA;Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston- Salem, NC, USA;Department of Dermatology, University of Southern Denmark, Odense, DenmarkCorrespondence[email protected]

References

Loft ND, Vaengebjerg S, Halling AS, et al. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies [Epub ahead of print]. J Eur Acad Dermatol Venereol. 2019.
PubMed Web of Science ®Google Scholar
D’Adamio S, Silvaggio D, Lombardo P, et al. The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis. Expert Opin Drug Saf. 2019;18:1031–1041.
PubMed Web of Science ®Google Scholar
Stander S, Kwon P, Hirman J, et al. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. J Am Acad Dermatol. 2019;80:1395–1402.
PubMed Web of Science ®Google Scholar
Hashimoto T, Yosipovitch G. Itching as a systemic disease. J Allergy Clin Immunol. 2019;144:375–380.
PubMed Web of Science ®Google Scholar
Kao J, Brickshawana A, Liewluck T. Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors. Curr Neurol Neurosci Rep. 2018;18(10):63.
Web of Science ®Google Scholar
Larkin J, Chmielowski B, Lao CD, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017;22:709–718.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Medications in dermatology are safer and more efficient than they used to be

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Medications in dermatology are safer and more efficient than they used to be

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date